Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). (4th May 2022)
- Record Type:
- Journal Article
- Title:
- Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). (4th May 2022)
- Main Title:
- Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
- Authors:
- Markati, Theodora
Fisher, Gemma
Ramdas, Sithara
Servais, Laurent - Abstract:
- ABSTRACT: Introduction: Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. Risdiplam is the third overall and first oral drug approved for SMA with disease-modifying potential. Risdiplam acts as a survival motor neuron 2 ( SMN2 ) pre-mRNA splicing modifier with satisfactory safety and efficacy profile. This review aims to critically appraise the place of risdiplam in the map of SMA therapeutics. Areas covered: This review gives an overview of the current market for SMA and presents the mechanism of action and the pharmacological properties of risdiplam. It also outlines the development of risdiplam from early preclinical stages through to the most recently published results from phase 2/3 clinical trials. Risdiplam has proved its efficacy in pivotal trials for SMA Types 1, 2, and 3 with a satisfactory safety profile. Expert opinion: In the absence of comparative data with the other two approved drugs, the role of risdiplam in the treatment algorithm of affected individuals is examined in three different patient populations based on the age and diagnosis method (newborn screening or clinical, symptom-driven diagnosis). Long-term data and real-world data will play a fundamental role in its future.
- Is Part Of:
- Expert opinion on investigational drugs. Volume 31:Number 5(2022)
- Journal:
- Expert opinion on investigational drugs
- Issue:
- Volume 31:Number 5(2022)
- Issue Display:
- Volume 31, Issue 5 (2022)
- Year:
- 2022
- Volume:
- 31
- Issue:
- 5
- Issue Sort Value:
- 2022-0031-0005-0000
- Page Start:
- 451
- Page End:
- 461
- Publication Date:
- 2022-05-04
- Subjects:
- Central nervous system (CNS) -- neuromuscular disorders -- risdiplam -- RNA splicing modifier -- SMN protein -- SMN1 gene -- SMN2 gene -- spinal muscular atrophy (SMA)
Drugs -- Design -- Periodicals
Drugs, Investigational -- Bibliography
Drugs, Investigational -- Periodicals
615.1 - Journal URLs:
- http://informahealthcare.com/journal/eid ↗
http://www.ashley-pub.com/loi/eid ↗
http://informahealthcare.com ↗
http://puck.ashley-pub.com/vl=7681552/cl=12/nw=1/rpsv/journal/journal5_home.htm ↗ - DOI:
- 10.1080/13543784.2022.2056836 ↗
- Languages:
- English
- ISSNs:
- 1354-3784
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002953
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21421.xml